Role of Serum Procalcitonin in Prediction of Severity in Patients with Acute Cholangitis

Abstract

Background Cholangitis is one of the commonest emergencies encountered by gastroenterologists that may warrant drainage of biliary system. Serum procalcitonin (PCT) is an important biomarker of cholangitis with a potential to guide early therapeutic decision.

Materials and Methods We did a retrospective analysis of prospectively maintained data of patients admitted in the hospital from March 2018 to September 2020 with a diagnosis of acute cholangitis based on Tokyo 18 guidelines (TG-18). All the demographic parameters, biochemical and hematological parameters, and the result were recorded.

Results One-hundred two patients were admitted to our hospital with a mean age of 51.07 ± 7.99 years, among which 58.5% (59/102) were females with most common etiology being choledocholithiasis (64%). Fever, jaundice, and abdominal pain were seen in 78% (80/102), 73.3% (74/102), and 76.9% (78/102) of patients, respectively. Organ failure was seen in 29.3% (29/102) of patients with most common organ failure being acute kidney injury. Mild, moderate, and severe cholangitis as per TG-13 was seen in 43.9, 26.8, and 29.3% of patients, respectively. Elevated PCT levels were associated with severe disease (76.7 vs. 26.5%, p < 0.05). Forty-three percent (44/102) patients were managed with delayed biliary drainage, while the majority of remaining specifically with raised PCT levels needed early endoscopic intervention.

Conclusion In this retrospective analysis, we showed that most common etiology of cholangitis in was choledocholithiasis. Raised serum PCT levels were significantly associated with increased severity of cholangitis.

Keywords

cholangitis - choledocholithiasis - procalcitonin

Ethical Statement

Not applicable.

Authors' Contribution

All authors contributed equally to the article.

Data Availability Statement

There is no data associated with this work.

Publication History

Received: 22 May 2023

Accepted: 14 September 2023

Article published online:
27 November 2023

• References

• 1 Kimura Y, Takada T, Kawarada Y. et al. Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007; 14 (01) 15-26
• 2 Huang T, Bass JA, Williams RD. The significance of biliary pressure in cholangitis. Arch Surg 1969; 98 (05) 629-632
• 3 Kiriyama S, Takada T, Strasberg SM. et al; Tokyo Guidelines Revision Committee. TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci 2013; 20 (01) 24-34
• 4 Covington EW, Roberts MZ, Dong J. Procalcitonin monitoring as a guide for antimicrobial therapy: a review of current literature. Pharmacotherapy 2018; 38 (05) 569-581
• 5 Self WH, Grijalva CG, Williams DJ. et al. Procalcitonin as an early marker of the need for invasive respiratory or vasopressor support in adults with community-acquired pneumonia. Chest 2016; 150 (04) 819-828
• 6 Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341 (8844) 515-518
• 7 Becker KL, Nylén ES, White JC, Müller B, Snider Jr RH. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89 (04) 1512-1525
• 8 Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36 (03) 941-952
• 9 Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34 (10) 2596-2602
• 10 Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39 (02) 206-217
• 11 Shinya S, Sasaki T, Yamashita Y. et al. Procalcitonin as a useful biomarker for determining the need to perform emergency biliary drainage in cases of acute cholangitis. J Hepatobiliary Pancreat Sci 2014; 21 (10) 777-785
• 12 Lee YS, Cho KB, Park KS, Lee JY, Lee YJ. Procalcitonin as a decision-supporting marker of urgent biliary decompression in acute cholangitis. Dig Dis Sci 2018; 63 (09) 2474-2479
• 13 Scheinpflug K, Schalk E, Grabert E, Achenbach HJ. Procalcitonin is not useful to discriminate between infectious and noninfectious CRP elevation in patients with non-small cell lung cancer. Infect Control Hosp Epidemiol 2015; 36 (09) 1117-1118
• 14 Grace E, Turner RM. Use of procalcitonin in patients with various degrees of chronic kidney disease including renal replacement therapy. Clin Infect Dis 2014; 59 (12) 1761-1767
• 15 Yokoe M, Takada T, Strasberg SM. et al; Tokyo Guidelines Revision Committee. TG13 diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci 2013; 20 (01) 35-46
• 16 Umefune G, Kogure H, Hamada T. et al. Procalcitonin is a useful biomarker to predict severe acute cholangitis: a single-center prospective study. J Gastroenterol 2017; 52 (06) 734-745
• 17 Hamano K, Noguchi O, Matsumoto Y. et al. Usefulness of procalcitonin for severity assessment in patients with acute cholangitis. Clin Lab 2013; 59 (1-2): 177-183
• 18 Dhar J, Samanta J, Birda CL. et al. Dynamics of serum procalcitonin for predicting outcome in patients of infected pancreatic necrosis. (UEG Week 2021 Poster Presentations). United European Gastroenterol J 2021; 9: 740
• 19 Jain A, Jena A, Gautam V, Samanta J, Sharma V, Mandavdhare HS. Role of change in the levels of inflammatory markers post drainage in predicting outcome in acute cholangitis. Arq Gastroenterol 2022; 59 (02) 212-218